Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The event offers live dial-in, instant telephone access, and a webcast via investor relations. A replay will be available on Corvus' website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CRVS
In the Mar 6 session, CRVS declined 1.65%, reflecting a mild negative market reaction. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 results | Positive | -1.4% | Q3 2025 financials and clinical milestones, with runway into Q4 2026. |
| Oct 28 | Q3 call scheduled | Neutral | +1.2% | Announcement of Nov 4, 2025 business update and Q3 2025 results call. |
| Aug 07 | Q2 2025 results | Positive | +4.4% | Q2 2025 results with positive soquelitinib data and stronger cash balance. |
| Jul 31 | Q2 call scheduled | Neutral | -1.7% | Scheduling of Aug 7, 2025 business update and Q2 2025 results call. |
| May 08 | Q1 2025 results | Positive | +32.2% | Q1 2025 results with favorable Phase 1 data and strengthened cash position. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings updates and results have generally coincided with modestly positive or strong upside moves, with only one recent earnings report showing a small negative reaction.
Over the past year, Corvus has repeatedly paired business updates with quarterly financial results, highlighting progress for soquelitinib and a T‑cell lymphoma Phase 3 program. Prior earnings releases on May 8, 2025, Aug 7, 2025 and Nov 4, 2025 emphasized strengthening cash positions, extended runway into Q4 2026, and increasing R&D spend. Scheduling calls ahead of results, as on Jul 31 and Oct 28, 2025, has been a recurring pattern, and the current announcement follows that same cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals:
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com and LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
